Xenon Pharmaceuticals (XENE) Non-Current Deffered Revenue (2013 - 2019)
Xenon Pharmaceuticals (XENE) reported Non-Current Deffered Revenue of $709000.0 for Q4 2019, up 332.32% quarter-over-quarter from $164000.0 in Q2 2015.
Xenon Pharmaceuticals (XENE) Non-Current Deffered Revenue (2013 - 2019) Analysis & Trends
Xenon Pharmaceuticals (XENE) has 4 years of Non-Current Deffered Revenue data on file, last reported at $709000.0 in Q4 2019.
- Non-Current Deffered Revenue for Q4 2019 came in at $709000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $709000.0 (changed N/A YoY), and the FY2019 annual result was $709000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue grew to $709000.0 in Q4 2019 per XENE's latest filing, from $164000.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $709000.0 in Q4 2019 and troughed at $164000.0 in Q2 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Xenon Pharmaceuticals | 4.61 Bn | 4.61 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 709,000.00 |
| Jun 30, 2015 | 164,000.00 |
| Mar 31, 2015 | 180,000.00 |
| Dec 31, 2014 | 157,000.00 |
| Sep 30, 2014 | 219,000.00 |
| Dec 31, 2013 | 11.89 Mn |